Direct-to-Consumer Genetic Testing Market Size to be USD 20.7 Billion by 2034; Rising Personalized Healthcare Demand to Augment Market Expansion

Download Sample

Published Date: February 2025

Direct-to-consumer genetic testing refers to genetic tests that are marketed directly to consumers without the need for a healthcare provider or medical intermediary. These tests provide insights into a wide range of genetic factors, including ancestry, health risks and carrier status for genetic conditions, personal traits, wellness, and even pharmacogenomics how individuals may respond to certain medications. Rising demand for personalized healthcare to boost direct-to-consumer genetic testing market during the forecast period.

Direct-to-Consumer Genetic Testing Market Segmentation Analysis:

By Test Type	Nutrigenomics Testing, Carrier Testing, Wellness & Fitness Testing, Predictive Testing, and Others
By Technology Type	Whole Genome Sequencing (WGS), Exome Sequencing, Next-Generation Sequencing (NGS), and Others
By Service Provider	In-house Laboratories, Third-Party Providers, and Pharmaceutical Partnerships
By Application	Personalized Medicine, Clinical Diagnostics, Research Applications, and Consumer Insights
By Distribution Channel	Online Platforms and Offline Platforms

Direct-to-Consumer Genetic Testing Market Report Highlights:

The direct-to-consumer genetic testing market size to be USD 20.7 Billion by 2034.
The market was worth USD 2.8 Billion in 2024.
The market is expanding at a CAGR of 24.5% during the forecast period.
North America is expected to lead the market during the forecast period.
Asia Pacific is projected to experience the rapid growth in the market during the forecast period.
By test type, the market is being dominated by the nutrigenomics testing segment.
The market is dominated by the whole genome sequencing (WGS) segment under technology type.
On the basis of service provider, the in-house laboratories segment holds the largest share of the market.
The direct-to-consumer genetic testing market is led by the clinical diagnostics application segment.
Based on distribution channel, the online platforms segment is growing with the highest growth rate in the market.

Direct-to-Consumer Genetic Testing Market Dynamics:

Growth Factor	Challenge Factor	Market Trend
High Demand for Personalized Healthcare	Privacy and Data Security Concerns	Surge in Specialty Genetic Testing Industries

Direct-to-Consumer Genetic Testing Market Key Highlights:

In June 2023, MyHeritage unveiled an upgraded ancestry test that now includes more detailed regional breakdowns, allowing users to trace their ancestry with greater specificity. This update comes in response to growing consumer interest in more granular genetic ancestry information.
In July 2023, in the wake of increasing demand for personalized healthcare services, 23andMe expanded its offerings by launching a new pharmacogenomics test, helping consumers understand how their genetics may affect their response to specific medications. This innovation underscores the shift from ancestry-focused tests toward health-oriented genetic services.

Direct-to-Consumer Genetic Testing Market Report Analysis:

Milestones in the Timeline of Direct-to-Consumer Genetic Testing –

1996: A U.K. genetic testing company launched mail-order genetic testing. In the United States, genetic testing companies marketed BRCA gene testing directly to consumers via newspapers.
1998: A clinical genetic testing company launched a consumer advertising campaign on television, on radio and in magazines.
2001: A nutrigenetics company in the United Kingdom marketed genetic tests to consumers directly via their website.
2003: The Human Genome Project was completed.
2005: The first DTC companies were founded.
2006: The US Government Accountability Office (GAO) investigated DTC-GT companies.
2007: DTC-GT was offered at USD 1,000.
2010: The Food and Drug Administration (FDA) initiated regulatory proceedings against DTC-GT companies.
2010: GAO released a report indicating that these companies made medically unproven disease predictions.
2012: DTC-GT prices dropped to USD 99.
2013: The FDA sent cease and desist letters to DTC-GT companies. In response, some DTC-GT companies elected to end their testing services. Others modified their products as instructed by the FDA, then worked closely with the FDA to ensure that existing and newly developed testing products met their standards.
2015: The FDA approved DTC-GT carrier screens.
2017: The FDA approved DTC-GT for certain health-related conditions.
2018: More than 26 million consumers had contributed their DNA to commercial databases.
2020: The FDA granted a DTC-GT company clearance for a pharmacogenetics report for interpretive drug information for two medications, clopidogrel and citalopram removing the need for confirmatory testing.

Browse ∼40 market data tables and ∼42 figures through ∼182 slides and in-depth TOC on “Direct-to-Consumer Genetic Testing Market Report Size, Share, By Test Type, Technology Type, Service Provider, Application, Distribution Channel, and Region - Trends, Analysis, and Forecast till 2034”

For more insights into the Direct-to-Consumer Genetic Testing Market and its future trends, visit the link: https://www.prophecymarketinsights.com/market_insight/direct-to-consumer-genetic-testing-market-5639

Direct-to-Consumer Genetic Testing Market Competitive Landscape:

The major players operating in the market are 23andMe, Inc., Ancestry.com LLC, MyHeritage Ltd., Living DNA Ltd., Helix OpCo LLC, Futura Genetics, Color Genomics, Inc., DNAfit, Counsyl, Inc., Veritas Genetics, MapMyGenome India Ltd., Orig3n, Inc., LetsGetChecked, Pathway Genomics Corporation, and EasyDNA.